TY  - JOUR
AU  - Fernandez-Martinez, Aranzazu
AU  - Pascual, Tomás
AU  - Perrone, Giuseppe
AU  - Morales, Serafin
AU  - de la Haba, Juan
AU  - González-Rivera, Milagros
AU  - Galván, Patricia
AU  - Zalfa, Francesca
AU  - Amato, Michela
AU  - Gonzalez, Lucia
AU  - Prats, Miquel
AU  - Rojo, Federico
AU  - Manso, Luis
AU  - Paré, Laia
AU  - Alonso, Immaculada
AU  - Albanell, Joan
AU  - Vivancos, Ana
AU  - González, Antonio
AU  - Matito, Judit
AU  - González, Sonia
AU  - Fernandez, Pedro
AU  - Adamo, Barbara
AU  - Muñoz, Montserrat
AU  - Viladot, Margarita
AU  - Font, Carme
AU  - Aya, Francisco
AU  - Vidal, Maria
AU  - Caballero, Rosalía
AU  - Carrasco, Eva
AU  - Altomare, Vittorio
AU  - Tonini, Giuseppe
AU  - Prat, Aleix
AU  - Martin, Miguel
PY  - 2017
DO  - 10.18632/oncotarget.15748
UR  - https://hdl.handle.net/10668/25130
T2  - Oncotarget
AB  - PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early...
LA  - en
KW  - Ki67
KW  - PAM50/Prosigna
KW  - breast cancer
KW  - estrogen receptor-positive/HER2-negative
KW  - Antineoplastic Agents, Hormonal
KW  - Biomarkers, Tumor
KW  - Breast Neoplasms
KW  - Chemotherapy, Adjuvant
KW  - Female
KW  - Follow-Up Studies
KW  - Gene Expression Profiling
KW  - Humans
KW  - Incidence
KW  - Neoplasm Recurrence, Local
KW  - Prognosis
KW  - Prospective Studies
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Risk Assessment
KW  - Tamoxifen
TI  - Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
TY  - research article
VL  - 8
ER  -